2 Green Flags and 1 Red Flag for Novartis Stock
Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates.
Novartis AG (NVS) Q3 2023 Earnings Call Transcript
Novartis AG (NYSE:NVS ) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Har...
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.
Novartis Raises Outlook After Sandoz Generics Spinoff
Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a pure-play innovative medicines “powerhouse.” He...
Novartis Begins New Era With Profit Beat and Guidance Hike
The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.
Novartis lifts 2023 earnings forecast for third time
Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.
Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.
Novartis leads funding round for UK Alzheimer's specialist
UK-based biotech firm AstronauTx has secured £48 million ($61 million) in a significant Series A funding round, marking a step towards developing treatments for Alzheimer's and other neurodegenerat...
Novartis (NVS) Ascends But Remains Behind Market: Some Facts to Note
Novartis (NVS) closed at $97.14 in the latest trading session, marking a +1.03% move from the prior day.
Novartis: Better Margin Visibility Ex-Sandoz
Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started tr...
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest develo...
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today
Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!
Novartis spin-off completed as Sandoz makes subdued start on Swiss bourse
Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down...
Related Companies